GlassScriptPhysician profile
Ilya M Karagodin
NPI 1609119932
$4,573.80
in general payments reported to CMS, 2019-2025
19 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $352 · 2021: $409 · 2022: $1,603 · 2023: $156 · 2024: $1,466 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,093 · Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,093.19 |
| Food and Beverage | $886.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,668.60 | 2021-2025 | Triclip, Cardiomems |
| Edwards Lifesciences Corporation | $1,372.54 | 2024-2025 | Evoque, Sapien 3 Ultra Resilia |
| Heartflow, INC. | $232.13 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $193.59 | 2020-2025 | Wainua |
| Janssen Pharmaceuticals, INC | $166.86 | 2019-2024 | Xarelto |
| Amgen INC. | $136.28 | 2019-2022 | |
| Pfizer INC. | $108.83 | 2019-2024 | |
| Lantheus Medical Imaging, INC. | $101.07 | 2019-2020 | |
| Philips North America LLC | $100.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.85 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $71.56 | 2021-2022 | |
| Acist Medical Systems, INC. | $64.00 | 2021 | |
| Novo Nordisk INC | $61.20 | 2024 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $56.71 | 2019 | |
| Alnylam Pharmaceuticals INC. | $44.15 | 2025 | Onpattro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.66 | 2024 | Verquvo |
| Bridgebio Pharma, INC. | $31.34 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Karagodin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.